Analysis of skeletal muscle reactivity induced by CDMNP-PEG-CD magnetic nanoparticles

doi:10.13418/j.issn.1001-165x.2022.2.11

PDF(18279 KB)

Chinese Journal of Clinical Anatomy ›› 2022, Vol. 40 ›› Issue (2) : 173-180. DOI: 10.13418/j.issn.1001-165x.2022.2.11

Analysis of skeletal muscle reactivity induced by CDMNP-PEG-CD magnetic nanoparticles

Jian Xiaoting¹, Wan Han¹, Huang Jingwen¹, Lan Haiqiang¹, Liao Zhaohong¹, Ke Yu², Liao Hua¹*, Zhu Chunmin ³*

Author information +

History +

Abstract

Objective　To investigate the immunoreactivity induced by SOMNP, CDMNP and CDMNP-PEG-CD magnetic nanoparticles implanted into mouse skeletal muscle.　Methods　SOMNP was prepared by compounding magnetic Fe3O4 and SiO2. Polyethylene glycol (PEG) and cyclodextrin (β-CD) molecules were linked to SOMNP to synthesize CDMNP, and polypseudorotaxanes were further added to synthesize CDMNP-PEG-CD magnetic nanoparticles. particles. Three kinds of nanoparticles were placed into the gastrocnemius muscle of B6 mice, respectively. Histochemical staining, immunofluorescence and FACS analysis were used to evaluate the characteristics of myotoxicity and intramuscular inflammatory exudation induced by SOMNP, CDMNP and CDMNP-PEG-CD nanoparticles at different implantation periods.　Results　Linking of SOMNP to β-CD, PEG/β-CD and polypseudorotaxanes will limit the intramuscular diffusion of nanoparticles, resulting in prolonged intramuscular residence time of CDMNP and CDMNP-PEG-CD, myocyte necrosis in the vicinity of the material, intramuscular mononuclear/Macrophage aggregation. Compared with CDMNP-PEG-CD, CDMNP nanoparticles attracted more T cells into muscle tissue. Conclusion　SOMNP, CDMNP and CDMNP-PEG-CD nanoparticles are all potential immune inducers in vivo. The modification of polypseudorotaxanes endowed CDMNP-PEG-CD nanoparticles with better in vivo compatibility.

Key words

Magnetic nanoparticles;　CDMNP-PEG-CD;　SOMNP;　CDMNP;　Immune response / Skeletal muscle　

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Jian Xiaoting, Wan Han, Huang Jingwen, Lan Haiqiang, Liao Zhaohong, Ke Yu, Liao Hua, Zhu Chunmin. Analysis of skeletal muscle reactivity induced by CDMNP-PEG-CD magnetic nanoparticles[J]. Chinese Journal of Clinical Anatomy. 2022, 40(2): 173-180 https://doi.org/10.13418/j.issn.1001-165x.2022.2.11

References

[1] Cortajarena AL, Ortega D, Ocampo SM, et al. Engineering Iron Oxide Nanoparticles for Clinical Settings[J]. Nanobiomedicine (Rij), 2014, 1:2. DOI: 10.5772/58841.
[2] Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface[J]. Nat Mater, 2009, 8(7):543-557. DOI: 10.1038/nmat2442
[3] Sakulkhu U, Mahmoudi M, Maurizi L, et al. Significance of surface charge and shell material of superparamagnetic iron oxide nanoparticle (SPION) based core/shell nanoparticles on the composition of the protein corona[J]. Biomater Sci, 2015, 3(2):265-278. DOI: 10.1039/c4bm00264d.
[4] Maboudi SA, Shojaosadati SA, Arpanaei A. Synthesis and characterization of multilayered nanobiohybrid magnetic particles for biomedical applications[J]. Materials & Design, 2017,115:317-324. DOI：10.1016/j.matdes.2016.11.064.
[5] Ke Y, Zhang X, Liu C, et al. Polypseudorotaxane functionalized magnetic nanoparticles as a dual responsive carrier for roxithromycin delivery[J]. Mater Sci Eng C Mater Biol Appl, 2019, 99:159-170. DOI: 10.1016/j.msec.2019.01.078.
[6] Yun YH, Lee BK, Park K. Controlled Drug Delivery: Historical perspective for the next generation[J]. J Control Release, 2015, 219: 2-7. DOI: 10.1016/j.jconrel.2015.10.005.
[7] Romera SA, Hilgers LA, Puntel M, et al. Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle.[J]. Vaccine, 2000, 19(1):132-141. DOI: 10.1016/s0264-410x(00)00104-3.
[8] Wu C, Xiang X, Yue Y, et al. CpG-PEG Conjugates and their immune modulating effects after systemic administration[J]. Pharmaceutical Research, 2018, 35(4): 80. DOI: 10.1007/s11095-018-2355-z.
[9] Yang Q, Lai S K. Anti-PEG immunity: emergence, characteristics, and unaddressed questions[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2015, 7(5): 655-677. DOI: 10.1002/wnan.1339.
[10] Tidball JG. Inflammatory processes in muscle injury and repair[J]. Am J Physiol Regul Integr Comp Physiol, 2005, 288(2):R345. DOI: 10.1152/ajpregu.00454.2004.
[11] Arnold L, Henry A, Poron F, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis[J]. J Exp Med, 2007, 204(5):1057-1069. DOI: 10.1084/jem.20070075.
[12] Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration[J]. Biomater Res, 2019, 23:20. DOI: 10.1186/s40824-019-0166-x.
[13] Takeuchi I, Nobata S, Oiri N, et al. Biodistribution and excretion of colloidal gold nanoparticles after intravenous injection: Effects of particle size[J]. Biomed Mater Eng, 2017, 28(3):315-323. DOI: 10.3233/BME-171677.
[14] Xie P, Yang S T, He T, et al. Bioaccumulation and toxicity of carbon nanoparticles suspension injection in intravenously exposed mice[J]. Int J Mol Sci, 2017, 18(12):2563. DOI: 10.3390/ijms18122562.
[15] Frank JA, Zywicke H, Jordan EK, et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents[J]. Acad Radiol, 2002, 9（Suppl 2）:S484-S487. DOI: 10.1016/s1076-6332(03)80271-4.
[16] Brigitte M, Schilte C, Plonquet A, et al. Muscle resident macrophages control the immune cell reaction in a mouse model of notexin-induced myoinjury[J]. Arthritis Rheum, 2010, 62(1):268-279. DOI: 10.1002/art.27183.
[17] Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells[J]. Arthritis Rheum, 2004, 50(1):199~208. DOI: 10.1002/art.11428.
[18] Jimenez-Perianez A, Abos GB, Lopez RJ, et al. Mesoporous silicon microparticles enhance MHC class I cross-antigen presentation by human dendritic cells[J]. Clin Dev Immunol, 2013, 2013:362163. DOI: 10.1155/2013/362163.